Back to Journals » Biologics: Targets and Therapy » Volume 15

Convalescent Plasma for the Treatment of Severe COVID-19

Authors Franchini M, Liumbruno GM

Received 4 December 2020

Accepted for publication 25 January 2021

Published 4 February 2021 Volume 2021:15 Pages 31—38

DOI https://doi.org/10.2147/BTT.S272063

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Professor Shein-Chung Chow


Massimo Franchini, Giancarlo Maria Liumbruno

Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantova, Italy

Correspondence: Massimo Franchini
Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantova, Italy
Tel +039-0376-201234
Fax +039-0376-220144
Email massimo.franchini@asst-mantova.it

Abstract: The COVID-19 pandemic in 2020 is one of the worst catastrophic events in human history. Several non-specific antiviral drugs have been tried to defeat the SARS-CoV-2, with mixed results. Convalescent plasma from patients who have recovered from COVID-19 is one of the specific biologic therapies being considered to treat SARS-CoV-2 infection. Preliminary studies have shown that convalescent plasma, containing antibodies able to neutralize SARS-CoV-2, is promising in blocking viral replication and improving patients’ clinical symptoms. The results of several ongoing randomized controlled trials are, however, keenly awaited to definitively elucidate the safety and efficacy of this blood component in COVID-19. In this narrative review, we summarize the current evidence from the literature on the treatment of severe COVID-19 with convalescent plasma. A concise overview of the hypothesized mechanisms of action is also presented.

Keywords: SARS-CoV-2, COVID-19, hyperimmune plasma, convalescent plasma, therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]